维普中文期刊产品整合服务
426篇 您的检索式:作者名="Karle C"
    题名 作者 年代 出处 被引量
1Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial显示文摘Roger Stupp Monika E Hegi Warren P Mason Martin J van den Bent Martin JB Taphoorn Robert C Janzer Samuel K Ludwin Anouk Allgeier Barbara Fisher Karl Belanger Peter Hau Alba A Brandes Johanna Gijtenbeek Christine Marosi Charles J Vecht Karima Mokhtari Piet 2009Lancet Oncology2009,,5:4
2Estimates of global terrestrial isoprene emissions using MEGAN (Model of Emissions of Gases and Aerosols from Nature)显示文摘Guenther A. Karl T. Harley P. Wiedinmyer C. Palmer P. I. Geron C 2006Atmospheric Chemistry and Physics2006,,68:2
3Management practices of hepatitis C virus infected alcoholic hepatitis patients:A survey of physicians显示文摘AIM:To survey gastroenterologists and hepatologists regarding their current views on treating hepatitis C virus(HCV) infected alcoholic hepatitis(AH) patients.METHODS:A sixteen item questionnaire was electronically mailed to gastroenterologists and hepatologists.A reminder was sent after 2 mo to increase the response rate.Participation of respondents was confidential.Accessing secured web site to respond to the questionnaire was considered as informed consent.Responses received on the secured website were downloaded in an excel sheet for data analysis.RESULTS:Analyzing 416 responses to 1556(27% response rate) emails,57% respondents(56% gastroenterologists) reported HCV prevalence > 20% amongst AH patients.Sixty nine percent often treated AH and 46% preferred corticosteroids(CS).Proportion of respondents with consensus(75% or more respondents agreeing on question) on specific management of HCV infected AH were:routine HCV testing(94%),HCV not changing response to CS(80%) or pentoxifylline(91%),no change in approach to treating HCV infected AH(75%).None of respondent variables:age,specialty,annual number of patients seen,and HCV prevalence could predict respondent to be in consensus on any of or all 4 questions.Further,only 4% would choose CS for treating HCV infected AH as opposed to 47% while treating HCV negative AH.CONCLUSION:Gastroenterologists and hepatologists believe that AH patients be routinely checked for HCV.However,there is lack of consensus on choice of drug for treatment and outcome of HCV positive AH patients.Studies are needed to develop guidelines for management of HCV infected AH patients.Ashwani K Singal Habeeb Salameh Anjna Singal Sarat C Jampana Daniel H Freeman Karl E Anderson Don Brunder 2013World Journal of Gastrointestinal Pharmacology and Therapeutics2013,4,2:2
4A vital sugar code for ricin toxicity显示文摘Jasmin Taubenschmld Johannes Stadlmann Markus Jost Tove Irene Klok.k Cory D Rillahan Andreas Leibbrandt Karl Mechtler James C Paulson Julian Jude Johannes Zuber Kirsten Sandvig Ulrich Elling Thorsten Marquardt Christian Thiel Christian Koerner Josef M Penninger 2017Cell Research2017,27,11:2
5紫杉醇局部治疗抑制猪静脉桥新生内膜形成和增厚的实验研究显示文摘目的 :局部药物治疗是一个很好的防治静脉桥病变的策略。本研究用抗细胞增殖药物紫杉醇处理大隐静脉桥后植入猪的颈动脉 ,以观察紫杉醇的抗细胞增殖作用在抑制静脉桥内膜平滑肌细胞增殖、迁移导致内膜形成和增厚的效果。方法 :将 10头猪的 2 0只大隐静脉桥分为两组。治疗组 :将大隐静脉桥 10只置于含有 10 μmol/L浓度的紫杉醇溶液中 (先用该溶液灌洗 )浸泡 1h后植入猪的颈动脉 ,紫杉醇是溶解在 2 5 μl/L的无水酒精中 ,对照组 10只大隐静脉桥置于单纯的酒精中浸泡。 4周后取开放的静脉桥进行组织学分析。结果 :①治疗组静脉桥新生内膜面积 (1 5 9± 0 95 )mm2 ,对照组新生内膜面积高达 (2 43± 1 3 5 )mm2 ,治疗组显著低于对照组 ,两组比较有非常显著的差异 ,P <0 0 1;②治疗组内膜平滑肌细胞密度均值为 (3 681± 193 5 ) /mm2 ,对照组为 (4 60 7± 1993 ) /mm2 ,两组比较有显著性差异 ,P <0 0 5 ;中膜平滑肌细胞密度均值治疗组 (2 13 9± 73 4) /mm2 ,对照组(3 62 9± 3 2 0 7) /mm2 ,两组比较有显著性的差异 ,P <0 0 5。结论 :紫杉醇可显著抑制静脉桥内膜、中膜平滑肌细胞的增殖 ,抑制新生内膜的形成 ,证明紫杉醇可在防治静脉桥闭塞方面发挥独特作用。吴隐雄 Martin H Chamberlain Thomas Johnson Jason L Johnson Andrew C Newby Gianni D Angelin Martin Oberhoff Karl K Karsch 2003中国循环杂志2003,18,6:2
6Erythropoietin therapy after out-of-hospital cardiac arrest:A systematic review and meta-analysis显示文摘AIM To assess safety and efficacy of early erythropoietin(Epo) administration in patients with out-of-hospital cardiac arrest(OHCA).METHODS A systematic literature search was performed using PubM ed,MEDLINE,EMBASE,EBSCO,CINAHL,Web of Science and Cochrane databases,of all studies published from the inception through October 10,2016.Inclusion criteria included:(1) Adult humans with OHCA and successful sustained return of spontaneous circulation;and(2) studies including mortality/brain death,acute thrombotic events as their end points.Primary efficacyoutcome was 'brain death or Cerebral Performance Category(CPC) score of 5'.Secondary outcomes were 'CPC score 1,and 2-4','overall thrombotic events' and 'acute coronary stent thrombosis'.RESULTS We analyzed a total of 606 participants(n = 276 received Epo and n = 330 with standard of care alone) who experienced OHCA enrolled in 3 clinical trials.No significant difference was observed between the Epo and no Epo group in brain death or CPC score 5(OR = 0.77;95%CI:0.42-1.39),CPC score 1(OR = 1.16,95%CI:0.82-1.64),and CPC score 2-4(OR = 0.77,95%CI:0.44-1.36).Epo group was associated with increased thrombotic complications(OR = 2.41,95%CI:1.26-4.62) and acute coronary stent thrombosis(OR = 8.16,95%CI:1.39-47.99).No publication bias was observed.CONCLUSION Our study demonstrates no improvement in neurological outcomes and increased incidence of thrombotic events and acute coronary stent thrombosis in OHCA patients who were treated with Epo in addition to standard therapy.Rahul Chaudhary Jalaj Garg Parasuram Krishnamoorthy Kevin Bliden Neeraj Shah Nayan Agarwal Rahul Gupta Abhishek Sharma Karl B Kern Nainesh C Patel Paul Gurbel 2017World Journal of Cardiology2017,9,12:2
7Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial显示文摘Faramarz Ismail-Beigi Timothy Craven Mary Ann Banerji Jan Basile Jorge Calles Robert M Cohen Robert Cuddihy William C Cushman Saul Genuth Richard H Grimm Bruce P Hamilton Byron Hoogwerf Diane Karl Lois Katz Armand Krikorian Patrick O'Connor Rodica Pop-Bus 2010The Lancet2010,,9739:2
8Hydrogen-bonded self-assembled peptide nanotubes from cystine-based macrocyclic bisureas显示文摘Ranganathan D Lskshmi C Karle I L 1999J Am Chem Soc1999,121,:1
9Transgenic zebrafish using transposable elements显示文摘Karl J C Mark D U Kimberly J 2011Methods Cell Biol2011,104,:1
10A variable force binder for a draw press显示文摘 Zhang S L Karl B O 1998Journal of Materials Processing Technology1998,73,:1
11Excitation-emission matrix fluorescence based determination of carbamate pesticides and polycyclic aromatic hydrocarbons显示文摘Renee D J Gary A C Karl S B 1999Analytica Chimica Acta1999,,397:1
12Easterling,First difference method:Maximum station density for the calculation of long-term global temperature change显示文摘PETERSON T C KARL T R JAMASON P F 1998J Geoghy Res1998,103,25:1
13Dynamic modeling of solid oxide fuel cell:The effect of diffusion and inherent impedance显示文摘QI Yu-tong HUANG Biao KARL T C 2005Power Sources2005,150,12:1
14Contributions of wastewater, runoff and sewer deposit erosion to wet weather pollutant loads in combined sewer systems显示文摘Gasperi J Gromaire M C Karl M 2010Water Research2010,44,20:1
15Promising practices in understaing andTreating child neglect 显示文摘Marianne B Renae C Karl D 2003Child and Family Soc Work2003,8,1:1
16Diet, Body Composition, and Physical Fitness Influences on IGF - 1 Bioac- tivity in Women 显示文摘KARL J P ALEMANY J A KOENIG C 2009Growtr Horm IGF Res2009,19,6:1
17The Wnt/Ca2+ path- way-a new vertibrate Wnt signaling pathway takes shape显示文摘Karl M Sheldahl L C Park M 2000Trends Genet2000,16,7:1
18Multiscale representations of Markov random fields显示文摘M R Luettgen W C Karl A S Willsky R R Tenney 1993IEEE Trans Signal Processing1993,41,12:1
19Acomparative study of ASOS And USCRN temperature measurements显示文摘Sun B Baker C B Karl T R 2005J Atmos Oceanic Technol2005,22,:1
20Community genomics among stratified microbial assemblages in the ocean's interior显示文摘DeLong E F Preston C M Mincer T Rich V Hallam S J Frigaard N U Martinez A Sullivan M B Edwards R Brito B R Chisholm S W Karl D M 0,,5760:1
返回顶部 每页显示:
共22页 首页 上一页 第1页 下一页 末页 /22 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费